Nordea Investment Management AB Boosts Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Nordea Investment Management AB raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,091 shares of the company’s stock after purchasing an additional 2,646 shares during the period. Nordea Investment Management AB’s holdings in Medpace were worth $19,402,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Wealth Alliance grew its stake in shares of Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after acquiring an additional 27 shares during the period. Centaurus Financial Inc. lifted its holdings in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Medpace by 0.7% during the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after purchasing an additional 32 shares during the period. Lindenwold Advisors INC increased its stake in shares of Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after purchasing an additional 37 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 2.2 %

Shares of NASDAQ MEDP opened at $354.59 on Thursday. The business has a 50-day moving average of $339.66 and a 200-day moving average of $360.59. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 1.91 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $277.72 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.22 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Truist Financial decreased their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.